Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub Sells 861 Shares

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 861 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $25.26, for a total transaction of $21,748.86. Following the completion of the sale, the director now directly owns 242,827 shares of the company’s stock, valued at approximately $6,133,810.02. This trade represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Weintraub also recently made the following trade(s):

• On Friday, December 13th, Michael Weintraub sold 20,565 shares of Phreesia stock. The stock was sold at an average price of $25.04, for a total value of $514,947.60.
• On Monday, December 2nd, Michael Weintraub sold 15,152 shares of Phreesia stock. The shares were sold at an average price of $21.01, for a total transaction of $318,343.52.

Phreesia Stock Performance

PHR stock traded down $0.77 during trading hours on Tuesday, reaching $24.87. The stock had a trading volume of 463,410 shares, compared to its average volume of 450,575. The stock has a 50-day simple moving average of $20.53 and a 200 day simple moving average of $21.84. The stock has a market capitalization of $1.45 billion, a PE ratio of -17.46 and a beta of 0.98. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.77. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $29.16.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The business had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia’s revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.58) earnings per share. Analysts predict that Phreesia, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC increased its stake in shares of Phreesia by 2,179.7% in the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after buying an additional 1,395 shares during the period. nVerses Capital LLC lifted its stake in shares of Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in Phreesia during the 2nd quarter worth approximately $202,000. Point72 DIFC Ltd purchased a new position in Phreesia during the 2nd quarter worth $209,000. Finally, XTX Topco Ltd bought a new stake in shares of Phreesia during the 3rd quarter worth $247,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on PHR. Truist Financial increased their target price on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $34.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. DA Davidson restated a “buy” rating and set a $32.00 target price on shares of Phreesia in a research report on Thursday, September 5th. JPMorgan Chase & Co. increased their price objective on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.